Avanir Pharmaceuticals Invites Investors to Its First Fiscal Quarter 2004 Conference Call on February 12.Business Editors SAN DIEGO--(BUSINESS WIRE)--Feb. 10, 2004 AVANIR Pharmaceuticals (AMEX AMEX See: American Stock Exchange :AVN AVN Aviation AVN Avenue AVN Adult Video News AVN Avascular Necrosis AVN Atrioventricular Node AVN Aviation Model (weather forecast model, now Global Forecast System) AVN Air Vanuatu (ICAO code) ) will hold its quarterly conference call on Thursday, February 12, 2004 at 10:00 a.m. Pacific/ 1:00 p.m. Eastern. A press release announcing first quarter 2004 financial results will be issued before the call on Thursday. The call will be web cast live by CCBN CCBN Central Coast Bancorp CCBN Charles County Business Network and can be accessed at AVANIR's web site at www.avanir.com. The webcast is being distributed over CCBN's investor distribution network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at www.companyboardroom.com or by visiting any of the investor sites in CCBN's Individual Investor Network. Institutional investors can access the call via CCBN's password protected event management site, StreetEvents (www.streetevents.com). For those who cannot listen to the live broadcast, the online replays will be available for 90 days, or a phone replay will be available through February 19, 2004, by dialing 888-266- 2081 and entering the passcode 389536. AVANIR Pharmaceuticals is a drug discovery and development company with a commercialized FDA-approved product (Abreva(R)) and products in clinical development for the treatment of pseudobulbar affect (Phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA ), neuropathic pain (Phase II), and allergy and asthma (Phase I). Through the use of its Xenerex(TM) technology, AVANIR also develops human monoclonal antibodies This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see "Nomenclature of monoclonal antibodies"). for infectious diseases infectious diseases: see communicable diseases. and other therapeutic applications. Further information about AVANIR can be found at www.avanir.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion